Salarius Pharmaceuticals Inc announces Fox Chase Cancer Center added as an active trial site for dose-expansion stage of ongoing clinical trial evaluating the company’s drug candidate, seclidemstat, in patients with relapsed or refractory Ewing sarcoma an

Media coverage

• Title	Salarius Pharmaceuticals Inc announces Fox Chase Cancer Center added as an active trial site for dose-expansion stage of ongoing clinical trial evaluating the company’s drug candidate, seclidemstat, in patients with relapsed or refractory Ewing sarcoma an
  Media name/outlet	Impact Financial News
  Country/Territory	United Kingdom
  Date	07/14/21
  Persons	Johnathan R. Whetstine